505596973 07/30/2019

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5643774

SUBMISSION TYPE:		NEW	NEW ASSIGNMENT					
NATURE OF CONVEYANCE:		ASSI	ASSIGNMENT					
CONVEYING PARTY	DATA							
		Name	Name			Ex	ecution Da	
NOVARTIS INSTITUT	ES FOR B	IOMEDICAL	DICAL RESEARCH INC.			07/	10/2017	
RECEIVING PARTY D	ΑΤΑ							
Name:	NOVA	NOVARTIS AG						
Street Address:	LICHT	LICHTSTRASSE 35						
City:	BASEL	BASEL						
State/Country:	SWITZ	SWITZERLAND						
Postal Code:	4056	4056						
PROPERTY NUMBER	RS Total: 1							
Property Type			Number					
		16291561	91561					
<i>using a fax number, i</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4:	be sent to if provided	<i>I; if that is u</i> 617871836 tara.melans TARA M MI 700 MAIN S 4TH FLOOI CAMBRIDG	on@novartis.com ELANSON STREET R iE, MASSACHUSETTS (sen	t via l		vill be sent	
ATTORNEY DOCKET NUMBER:		PATO	PAT057146-US-CNT02					
NAME OF SUBMITTER:			TARA M MELANSON					
			/Tara M Melanson/					
DATE SIGNED:			07/30/2019					
Total Attachments: 2 source=US_confirmator source=US_confirmator								

INTERNATIONAL CONFIRMATORY ASSIGNMENT

This Assignment between

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. of 181 Massachusetts Avenue, Cambridge, MA 02139, USA

(hereinafter referred to as ASSIGNOR)

AND NOVARTIS AG of Lichtstrasse 35, 4056 Basel, Switzerland (hereinafter referred to as ASSIGNEE)

WHEREAS ASSIGNOR is the successor in interest to all legal rights and assets of **ADMUNE THERAPEUTICS LLC** of **107 Water Street**, **Danvers**, **MA 01923**, **USA** (hereinafter referred to as ADMUNE) as a result of the merger of ADMUNE with and into ASSIGNOR as of June 20, 2017.

WHEREAS, as a result, the ASSIGNOR is the applicant/holder of the patent application number(s) listed on the attached Schedule (formerly held by ADMUNE).

And WHEREAS the ASSIGNOR does hereby confirm that by virtue of an agreement dated October 16, 2015 (the "Agreement"), ADMUNE agreed to assign all its right, title and interest in the said patent to the ASSIGNEE upon the terms hererin set out (as to which Agreement ASSIGNOR obtained all rights and obligations as a result of such merger).

<u>NOW IT IS AGREED</u> that in pursuance of the said Agreement the ASSIGNOR hereby assigns for good and valuable consideration and set over unto the ASSIGNEE all their right, title and interest in and to the said inventions and Letters Patent and the sole and exclusive benefits thereof and rights, powers and advantages whatsoever in or in respect of the said invention and Letters Patent TO HOLD the same unto the ASSIGNEE absolutely.

IN WITNESS THEREOF these presents have been executed by the parties, hereto in accordance with their respective constitutions the day written below.

EXECUTED on behalf of **Novartis Institutes for Biomedical Research**, Inc. by the undersigned authorized officer thereof in the presence of the undersigned competent witness.

Name: Scott Brown Position: secretary Place: Countridge, Ma, JA Date: July 10, 2017

Name: Shannon Kelliber Position: Demois Animont, MAR Legal Place: (autority, Mapaisg Date: 7/10/17

EXECUTED on behalf of Novartis AG by the undersigned authorized officer thereof in the presence of the undersigned competent witness.

Sign:

Name: Sarah Thompson Position: Service Patent Attorney Place: Basel Date: 18th July 2017

Name: Given acconation they a J. Fernice Menu Position: PARALEERE PARALEERE Date: jon July 2019 Place:

PATENT REEL: 049906 FRAME: 0682

Sign: 🖌 Name: Lachlan Campbell Position: Europe Chemistry Head NIBR Patents Place: Basel, Switzerland Date: 18 July 2017

ê (Gaard Kiisife J. pon wi fosti Witness: Name: Jun CERANE (" Position: Poralegent Place: Fred

Roales Roales 2017

Schedule

Country	Application/Patent Number	Novartis Reference Number		
United States of America	12/666052	• PAT057146-US-PCT		
United States of America	14/436523	PAT057145-US-PCT		
United States of America	62/030394	PAT057151-US-PSP		

RECORDED: 07/30/2019